# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement wit...
BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $8 to $11.
Partnership Includes Access to panCELLa™ Platform for Generating Hypoimmune Cells for Clinical Implantation
Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte (NASDAQ:HUMA) with a Overweight and maintains $7 price target.
Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.